Company Overview and News
New Talisman Gold Mines Ltd’s (ASX:NTL) test work has recovered 94% and 93.6% gold from ore samples taken from two target areas of the Talisman Mine in New Zealand.
New Talisman Gold Mines (ASX:NTL) will offer compliant investors the opportunity to take up shortfall shares due to interest received from several investors and shareholders.
New Talisman Gold Mines Ltd (ASX:NTL,NZSX:NTL) has pounced on 100% of Newcrest New Zealand Exploration Pty Ltd, a subsidiary of Newcrest Mining Ltd (ASX:NCM).
New Talisman Gold Mines Ltd (ASX:NTL,NZSX:NTL) has outlined that the current Share Purchase Plan (SPP) will not be extended and will close at 5.00pm (NZ time) and 3.00pm (AEST) on the 20th September.
New Talisman Gold Mines Ltd (ASX:NTL, NZX:NTL) is one of the best performing stocks in Australia and New Zealand recently, with the current price of $0.023 making it a four-bagger in two months.
New Talisman Gold Mines (ASX:NTL) has increased both the gold resource size and grade of the Woodstock zone within the 100% owned Talisman Gold Mine located in New Zealand.
New Talisman Gold Mines (ASX:NTL) has completed site works at surface and is advancing underground refurbishments at its 100% owned Talisman Mine in New Zealand.
The ASX 200 opened the session in negative territory (down 15.8 points 5713.10), tracking the US market, which was unsettled by the unfolding Trump junior email scandal.
New Talisman Gold Mines Ltd (ASX:NTL) has increased its JORC resource by 102% to 312,800 ounces gold grading 21.98 g/t at its 100% owned Talisman Gold Mine in New Zealand.
11h - Asif
Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...
11h - Asif
Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...
2018-04-23 - Asif
Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...